Home hemodialysis: a comparison of in-center and home hemodialysis therapy in a cohort of successful home hemodialysis patients.
We retrospectively evaluated 29 patients dialyzed for 6 months in-center on Fresenius 2008H or 2008K dialysis machines followed by 6 months at home using the Fresenius 2008K@home to determine the safety and efficacy of home hemodialysis (HHD) using the 2008K@home. Patients who initiated HHD were identified from order records and qualified for inclusion if they had available records and a minimum of three pre- and postdialysis blood urea nitrogen measurements during each period. Dialysis adequacy (mean standard weekly Kt/V) remained stable during the in-center (IC; 2.3 +/- 0.7 start, 2.3 +/- 0.7 end) and home periods (2.4 +/- 0.6 start, 2.5 +/- 0.7 end). During the home period, the percentage of delivered/prescribed single pool Kt/V was 96% +/- 12%; delivered/prescribed treatment time 98% +/- 10%; delivered/prescribed blood flow 95% +/- 7%, and delivered/prescribed dialysate flow was 99% +/- 8%. Twelve patients had 69 adverse events (5.84/100 treatments) IC and 18 patients had 40 (3.34/100 treatments) at home. No deaths were reported. In conclusion, a group of successful HHD patients received their prescribed hemodialysis therapy with the same or better adequacy as provided IC with no increase in adverse events. This demonstrates that selected patients can deliver HHD as safely and effectively as when receiving hemodialysis IC.
Sands
Jeffrey J
JJ
Renal Therapies Group, Fresenius Medical Care North America, Celebration, Florida 34747, USA. Jeffrey.Sands@fmc-na.com
Lacson
Eduardo
E
Ofsthun
Norma J
NJ
Kay
Janet C
JC
Diaz-Buxo
Jose A
JA
D000328:Adult; D001806:Blood Urea Nitrogen; D015331:Cohort Studies; D005260:Female; D006437:Hemodialysis, Home / Q000009:adverse effects* / Q000379:methods*; D006760:Hospitalization; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D012107:Research Design; D012709:Serum Albumin / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
D012709:Serum Albumin